137 related articles for article (PubMed ID: 12194942)
21. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA
Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164
[TBL] [Abstract][Full Text] [Related]
22. Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9.
Tsao CC; Wester MR; Ghanayem B; Coulter SJ; Chanas B; Johnson EF; Goldstein JA
Biochemistry; 2001 Feb; 40(7):1937-44. PubMed ID: 11329260
[TBL] [Abstract][Full Text] [Related]
23. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
24. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
[No Abstract] [Full Text] [Related]
25. [Individualization of drug therapy and pharmacogenetics].
Yamamoto I; Azuma J
Nihon Rinsho; 1998 Mar; 56(3):579-83. PubMed ID: 9549339
[TBL] [Abstract][Full Text] [Related]
26. Warfarin dose requirement and CYP2C9 polymorphisms.
Halkin H; Lubetsky A
Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
[No Abstract] [Full Text] [Related]
27. CYP2C9 polymorphism and warfarin dose requirements.
Daly AK; Day CP; Aithal GP
Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
[No Abstract] [Full Text] [Related]
28. [Status of pharmacogenomics and its future role in drug therapy].
Cascorbi I
Internist (Berl); 2002 Apr; 43(4):506-10. PubMed ID: 12053407
[No Abstract] [Full Text] [Related]
29. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
[No Abstract] [Full Text] [Related]
30. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
31. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
33. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.
de Morais SM; Schweikl H; Blaisdell J; Goldstein JA
Biochem Biophys Res Commun; 1993 Jul; 194(1):194-201. PubMed ID: 8333835
[TBL] [Abstract][Full Text] [Related]
34. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County.
London SJ; Sullivan-Klose T; Daly AK; Idle JR
Pharmacogenetics; 1997 Oct; 7(5):401-4. PubMed ID: 9352577
[No Abstract] [Full Text] [Related]
35. Mutations of the CYP2C9 gene and the response to warfarin.
Yasar U; Oscarson M; Eliasson E; Sjöqvist F
Surgery; 2001 Mar; 129(3):384. PubMed ID: 11231472
[No Abstract] [Full Text] [Related]
36. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
37. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
Yasar U; Eliasson E; Dahl ML
Carcinogenesis; 2002 Apr; 23(4):665; author reply 667-8. PubMed ID: 11960920
[No Abstract] [Full Text] [Related]
38. Transcriptional activation of CYP2C, MxA and Fas in sudden infant death syndrome.
Beurton F; Gueret G; Horisberger M; Cheron G; Cresteil T
Int J Mol Med; 1999 Jan; 3(1):33-9. PubMed ID: 9864383
[TBL] [Abstract][Full Text] [Related]
39. Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms.
Tabrizi AR; McGrath SD; Blinder MA; Buchman TG; Zehnbauer BA; Freeman BD
Am J Hematol; 2001 Jun; 67(2):144-6. PubMed ID: 11343389
[TBL] [Abstract][Full Text] [Related]
40. CYP2C9*3 allelic variant and bleeding complications.
Ogg MS; Brennan P; Meade T; Humphries SE
Lancet; 1999 Sep; 354(9184):1124. PubMed ID: 10509530
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
